Daré Bioscience, Inc. (DARE)
Oxford Ledge is still expanding full research coverage of DARE. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Dar Bioscience develops women's health products through FDA approval and alternative regulatory pathways, with early commercial launches and a clinical pipeline.
SEC filings
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-07-13
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-06-22
- 8-K Departure/election of directors or officers; Shareholder vote results; Financial statements and exhibits 2026-06-12
- 8-K 3.02 2026-05-18
- 10-Q Quarterly financial report (unaudited) 2026-05-14
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for DARE. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open DARE in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.